Karyopharm Therapeutics Inc. (NASDAQ:KPTI)’s share price dropped 3.2% on Wednesday . The stock traded as low as $7.23 and last traded at $7.29, with a volume of 73,450 shares trading hands. The stock had previously closed at $7.53.

KPTI has been the topic of several research analyst reports. Bank of America Corp. lowered Karyopharm Therapeutics from a “neutral” rating to an “underperform” rating and reduced their price objective for the company from $26.00 to $11.00 in a research note on Tuesday, March 15th. Canaccord Genuity reiterated a “buy” rating and set a $20.00 target price on shares of Karyopharm Therapeutics in a report on Wednesday, April 6th. Wedbush reiterated an “outperform” rating and set a $16.00 target price (down from $38.00) on shares of Karyopharm Therapeutics in a report on Tuesday, March 15th. Robert W. Baird began coverage on Karyopharm Therapeutics in a report on Monday, June 27th. They set an “outperform” rating and a $16.00 target price on the stock. Finally, Leerink Swann reiterated a “buy” rating on shares of Karyopharm Therapeutics in a report on Monday, June 27th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $19.50.

The firm’s market cap is $257.83 million. The stock has a 50 day moving average of $8.19 and a 200-day moving average of $8.14.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Monday, May 9th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by $0.01. Analysts anticipate that Karyopharm Therapeutics Inc. will post ($3.09) earnings per share for the current fiscal year.

In other Karyopharm Therapeutics news, major shareholder Ltd Chione sold 10,400 shares of the business’s stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $8.01, for a total value of $83,304.00. Following the transaction, the insider now owns 8,967,732 shares in the company, valued at $71,831,533.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

An institutional investor recently raised its position in Karyopharm Therapeutics stock. Mutual of America Capital Management LLC increased its stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 60.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 88,066 shares of the company’s stock after buying an additional 33,129 shares during the period. Mutual of America Capital Management LLC owned approximately 0.25% of Karyopharm Therapeutics worth $1,167,000 as of its most recent filing with the SEC.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other diseases. The Company is developing small molecule Selective Inhibitor of Nuclear Export (SINE), compounds that inhibits the nuclear export protein XPO1.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.